कृपया अन्य खोज का प्रयास करें
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Daniel J. Wallace | - | - | Member of Clinical Advisory Board |
Osnat Hillel Fain | 55 | 2015 | Independent Non-Executive & External Director |
Murray Urowitz | - | - | Member of Clinical Advisory Board |
Robert I. Fox | - | 2017 | Member of Clinical Advisory Board |
Lee S. Simon | 70 | - | Member of Clinical Advisory Board |
Simon Bowman | - | 2017 | Member of Clinical Advisory Board |
David Isenberg | - | 2015 | Member of Clinical Advisory Board |
Jonathan Schapiro | 61 | 2014 | Non-Executive Director |
Shlomo Spokone Shalev | 59 | 2014 | CEO & Director |
Doron Turgeman | 53 | 2014 | Non-Executive Chairman of the Board |
Alexander Rabinovich | 51 | 2017 | Non-Executive Director |
Dobroslav Melamed | 46 | 2014 | Independent Non-Executive Director |
Iris Shapira Yalon | 56 | 2020 | Independent Non-Executive & External Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है